Artykuły prasowe

Dotyczące czerniaka

Metastatic melanoma – a review of current and future treatment options. Acta Derm Venereol.

2015 Apr. Maverakis E1, Cornelius LA, Bowen GM, Phan T, Patel FB, Fitzmaurice S, He Y, Burrall B, Duong C, Kloxin AM, Sultani H, Wilken R, Martinez SR, Patel F

http://www.ncbi.nlm.nih.gov/pubmed/25520039

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther.

2015 Apr. Mahoney KM1, Freeman GJ2, McDermott DF3.

http://www.ncbi.nlm.nih.gov/pubmed/25823918

Risk of subsequent melanoma after melanoma in situ and invasive melanoma: A population-based study from 1973 to 2011.

Pomerantz H1, Huang D2, Weinstock MA3. J Am Acad Dermatol. 2015 May

http://www.ncbi.nlm.nih.gov/pubmed

Diagnosis and management of lentigo maligna: a review. Drugs Context.

2015 May 29 Kasprzak JM1, Xu YG1.

http://www.ncbi.nlm.nih.gov/pubmed/26082796

Dotyczące raków skóry

Interventions for cutaneous Bowen’s disease. Cochrane Database Syst Rev.

2013 Jun 24 Bath-Hextall FJ1, Matin RN, Wilkinson D, Leonardi-Bee J.

http://www.ncbi.nlm.nih.gov/pubmed

Basal cell carcinoma: an evidence-based treatment update.

Clark CM1, Furniss M, Mackay-Wiggan JM. Am J Clin Dermatol. 2014 Jul;

http://www.ncbi.nlm.nih.gov/pubmed/24733429

Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma.

Oncologist. 2014 Aug;19 Dreno B, Basset-Seguin N, Caro I, Yue H, Schadendorf D

http://www.ncbi.nlm.nih.gov/pubmed/

Topical Treatment Strategies for Non-Melanoma Skin Cancer and Precursor Lesions.

Semin Cutan Med Surg 23:174-183 © 2004 Elsevier S. Teri McGillis, MD, and Howard Fein

Interventions for basal cell carcinoma of the skin.

Cochrane Database Syst Rev. 2007 Jan 24 , Perkins W, Bong J, Williams HC

http://www.ncbi.nlm.nih.gov/pubmed/17253489

Dotyczące chłoniaków

Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.

J Am Acad Dermatol. 2014 Feb, Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C

http://www.ncbi.nlm.nih.gov/pubmed/24438969

Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.

J Am Acad Dermatol. 2014 Feb Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C

http://www.ncbi.nlm.nih.gov/pubmed/24438970

Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)

Br J Haematol. 2011 Oct Wong HK, Mishra A, Hake T, Porcu P.

http://www.ncbi.nlm.nih.gov/pubmed/21883142

The utility of bexarotene in mycosis fungoides and Sézary syndrome.

Onco Targets Ther. 2015 Feb, Panchal MR, Scarisbrick JJ.

http://www.ncbi.nlm.nih.gov/pubmed/25678803

Hydrochlorothiazid and cutaneous T cell lymphoma : prospective analysis and case series.

Cancer 2013 Jahan-Tigh RR, Huen AO, Lee GL, Pozadzides JV, Liu P, Duvic M.

http://www.ncbi.nlm.nih.gov/pubmed/